Table of Contents 1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered: Ranking by NSCLS Drugs Revenue 1.4 Market Analysis by Type 1.4.1 Global NSCLS Drugs Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 EGFR Targeting 1.4.3 ALK Targeting 1.4.4 PD-1/PD-L1 Targeting 1.4.5 Gemcitabine 1.4.6 Cisplatin/Carboplatin 1.4.7 Pemetrexed 1.4.8 Paclitaxel 1.4.9 Others 1.5 Market by Application 1.5.1 Global NSCLS Drugs Market Share by Application: 2020 VS 2026 1.5.2 ≤ 30 Years Old 1.5.3 31 - 45 Years Old 1.5.4 46 - 60 Years Old 1.5.5 ＞ 60 Years Old 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions 2.1 NSCLS Drugs Market Perspective (2015-2026) 2.2 NSCLS Drugs Growth Trends by Regions 2.2.1 NSCLS Drugs Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 NSCLS Drugs Historic Market Share by Regions (2015-2020) 2.2.3 NSCLS Drugs Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porter’s Five Forces Analysis 2.3.5 NSCLS Drugs Market Growth Strategy 2.3.6 Primary Interviews with Key NSCLS Drugs Players (Opinion Leaders) 3 Competition Landscape by Key Players 3.1 Global Top NSCLS Drugs Players by Market Size 3.1.1 Global Top NSCLS Drugs Players by Revenue (2015-2020) 3.1.2 Global NSCLS Drugs Revenue Market Share by Players (2015-2020) 3.1.3 Global NSCLS Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.2 Global NSCLS Drugs Market Concentration Ratio 3.2.1 Global NSCLS Drugs Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by NSCLS Drugs Revenue in 2019 3.3 NSCLS Drugs Key Players Head office and Area Served 3.4 Key Players NSCLS Drugs Product Solution and Service 3.5 Date of Enter into NSCLS Drugs Market 3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global NSCLS Drugs Historic Market Size by Type (2015-2020) 4.2 Global NSCLS Drugs Forecasted Market Size by Type (2021-2026) 5 NSCLS Drugs Breakdown Data by Application (2015-2026) 5.1 Global NSCLS Drugs Market Size by Application (2015-2020) 5.2 Global NSCLS Drugs Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America NSCLS Drugs Market Size (2015-2020) 6.2 NSCLS Drugs Key Players in North America (2019-2020) 6.3 North America NSCLS Drugs Market Size by Type (2015-2020) 6.4 North America NSCLS Drugs Market Size by Application (2015-2020) 7 Europe 7.1 Europe NSCLS Drugs Market Size (2015-2020) 7.2 NSCLS Drugs Key Players in Europe (2019-2020) 7.3 Europe NSCLS Drugs Market Size by Type (2015-2020) 7.4 Europe NSCLS Drugs Market Size by Application (2015-2020) 8 China 8.1 China NSCLS Drugs Market Size (2015-2020) 8.2 NSCLS Drugs Key Players in China (2019-2020) 8.3 China NSCLS Drugs Market Size by Type (2015-2020) 8.4 China NSCLS Drugs Market Size by Application (2015-2020) 9 Japan 9.1 Japan NSCLS Drugs Market Size (2015-2020) 9.2 NSCLS Drugs Key Players in Japan (2019-2020) 9.3 Japan NSCLS Drugs Market Size by Type (2015-2020) 9.4 Japan NSCLS Drugs Market Size by Application (2015-2020) 10 Southeast Asia 10.1 Southeast Asia NSCLS Drugs Market Size (2015-2020) 10.2 NSCLS Drugs Key Players in Southeast Asia (2019-2020) 10.3 Southeast Asia NSCLS Drugs Market Size by Type (2015-2020) 10.4 Southeast Asia NSCLS Drugs Market Size by Application (2015-2020) 11 India 11.1 India NSCLS Drugs Market Size (2015-2020) 11.2 NSCLS Drugs Key Players in India (2019-2020) 11.3 India NSCLS Drugs Market Size by Type (2015-2020) 11.4 India NSCLS Drugs Market Size by Application (2015-2020) 12 Central & South America 12.1 Central & South America NSCLS Drugs Market Size (2015-2020) 12.2 NSCLS Drugs Key Players in Central & South America (2019-2020) 12.3 Central & South America NSCLS Drugs Market Size by Type (2015-2020) 12.4 Central & South America NSCLS Drugs Market Size by Application (2015-2020) 13Key Players Profiles 13.1 Roche 13.1.1 Roche Company Details 13.1.2 Roche Business Overview and Its Total Revenue 13.1.3 Roche NSCLS Drugs Introduction 13.1.4 Roche Revenue in NSCLS Drugs Business (2015-2020)) 13.1.5 Roche Recent Development 13.2 Novartis 13.2.1 Novartis Company Details 13.2.2 Novartis Business Overview and Its Total Revenue 13.2.3 Novartis NSCLS Drugs Introduction 13.2.4 Novartis Revenue in NSCLS Drugs Business (2015-2020) 13.2.5 Novartis Recent Development 13.3 Pfizer 13.3.1 Pfizer Company Details 13.3.2 Pfizer Business Overview and Its Total Revenue 13.3.3 Pfizer NSCLS Drugs Introduction 13.3.4 Pfizer Revenue in NSCLS Drugs Business (2015-2020) 13.3.5 Pfizer Recent Development 13.4 Merck 13.4.1 Merck Company Details 13.4.2 Merck Business Overview and Its Total Revenue 13.4.3 Merck NSCLS Drugs Introduction 13.4.4 Merck Revenue in NSCLS Drugs Business (2015-2020) 13.4.5 Merck Recent Development 13.5 Bristol-Myers Squibb 13.5.1 Bristol-Myers Squibb Company Details 13.5.2 Bristol-Myers Squibb Business Overview and Its Total Revenue 13.5.3 Bristol-Myers Squibb NSCLS Drugs Introduction 13.5.4 Bristol-Myers Squibb Revenue in NSCLS Drugs Business (2015-2020) 13.5.5 Bristol-Myers Squibb Recent Development 13.6 Eli Lilly and Company 13.6.1 Eli Lilly and Company Company Details 13.6.2 Eli Lilly and Company Business Overview and Its Total Revenue 13.6.3 Eli Lilly and Company NSCLS Drugs Introduction 13.6.4 Eli Lilly and Company Revenue in NSCLS Drugs Business (2015-2020) 13.6.5 Eli Lilly and Company Recent Development 13.7 Takeda Pharmaceutical 13.7.1 Takeda Pharmaceutical Company Details 13.7.2 Takeda Pharmaceutical Business Overview and Its Total Revenue 13.7.3 Takeda Pharmaceutical NSCLS Drugs Introduction 13.7.4 Takeda Pharmaceutical Revenue in NSCLS Drugs Business (2015-2020) 13.7.5 Takeda Pharmaceutical Recent Development 13.8 Boehringer-Ingelheim 13.8.1 Boehringer-Ingelheim Company Details 13.8.2 Boehringer-Ingelheim Business Overview and Its Total Revenue 13.8.3 Boehringer-Ingelheim NSCLS Drugs Introduction 13.8.4 Boehringer-Ingelheim Revenue in NSCLS Drugs Business (2015-2020) 13.8.5 Boehringer-Ingelheim Recent Development 13.9 AstraZeneca 13.9.1 AstraZeneca Company Details 13.9.2 AstraZeneca Business Overview and Its Total Revenue 13.9.3 AstraZeneca NSCLS Drugs Introduction 13.9.4 AstraZeneca Revenue in NSCLS Drugs Business (2015-2020) 13.9.5 AstraZeneca Recent Development 13.10 Betta Pharmaceuticals 13.10.1 Betta Pharmaceuticals Company Details 13.10.2 Betta Pharmaceuticals Business Overview and Its Total Revenue 13.10.3 Betta Pharmaceuticals NSCLS Drugs Introduction 13.10.4 Betta Pharmaceuticals Revenue in NSCLS Drugs Business (2015-2020) 13.10.5 Betta Pharmaceuticals Recent Development 13.11 Qilu Oharmaceutical 10.11.1 Qilu Oharmaceutical Company Details 10.11.2 Qilu Oharmaceutical Business Overview and Its Total Revenue 10.11.3 Qilu Oharmaceutical NSCLS Drugs Introduction 10.11.4 Qilu Oharmaceutical Revenue in NSCLS Drugs Business (2015-2020) 10.11.5 Qilu Oharmaceutical Recent Development 13.12 Pierre Fabre Medicament 10.12.1 Pierre Fabre Medicament Company Details 10.12.2 Pierre Fabre Medicament Business Overview and Its Total Revenue 10.12.3 Pierre Fabre Medicament NSCLS Drugs Introduction 10.12.4 Pierre Fabre Medicament Revenue in NSCLS Drugs Business (2015-2020) 10.12.5 Pierre Fabre Medicament Recent Development 13.13 Chemo Wanbang Biopharma 10.13.1 Chemo Wanbang Biopharma Company Details 10.13.2 Chemo Wanbang Biopharma Business Overview and Its Total Revenue 10.13.3 Chemo Wanbang Biopharma NSCLS Drugs Introduction 10.13.4 Chemo Wanbang Biopharma Revenue in NSCLS Drugs Business (2015-2020) 10.13.5 Chemo Wanbang Biopharma Recent Development 13.14 Hetero Drugs 10.14.1 Hetero Drugs Company Details 10.14.2 Hetero Drugs Business Overview and Its Total Revenue 10.14.3 Hetero Drugs NSCLS Drugs Introduction 10.14.4 Hetero Drugs Revenue in NSCLS Drugs Business (2015-2020) 10.14.5 Hetero Drugs Recent Development 13.15 Harbin Gloria Pharmaceuticals 10.15.1 Harbin Gloria Pharmaceuticals Company Details 10.15.2 Harbin Gloria Pharmaceuticals Business Overview and Its Total Revenue 10.15.3 Harbin Gloria Pharmaceuticals NSCLS Drugs Introduction 10.15.4 Harbin Gloria Pharmaceuticals Revenue in NSCLS Drugs Business (2015-2020) 10.15.5 Harbin Gloria Pharmaceuticals Recent Development 13.16 Luoxin Pharmaceutical 10.16.1 Luoxin Pharmaceutical Company Details 10.16.2 Luoxin Pharmaceutical Business Overview and Its Total Revenue 10.16.3 Luoxin Pharmaceutical NSCLS Drugs Introduction 10.16.4 Luoxin Pharmaceutical Revenue in NSCLS Drugs Business (2015-2020) 10.16.5 Luoxin Pharmaceutical Recent Development 13.17 Teva Pharmaceutical 10.17.1 Teva Pharmaceutical Company Details 10.17.2 Teva Pharmaceutical Business Overview and Its Total Revenue 10.17.3 Teva Pharmaceutical NSCLS Drugs Introduction 10.17.4 Teva Pharmaceutical Revenue in NSCLS Drugs Business (2015-2020) 10.17.5 Teva Pharmaceutical Recent Development 13.18 Mylan 10.18.1 Mylan Company Details 10.18.2 Mylan Business Overview and Its Total Revenue 10.18.3 Mylan NSCLS Drugs Introduction 10.18.4 Mylan Revenue in NSCLS Drugs Business (2015-2020) 10.18.5 Mylan Recent Development 13.19 Sun Pharmaceutical 10.19.1 Sun Pharmaceutical Company Details 10.19.2 Sun Pharmaceutical Business Overview and Its Total Revenue 10.19.3 Sun Pharmaceutical NSCLS Drugs Introduction 10.19.4 Sun Pharmaceutical Revenue in NSCLS Drugs Business (2015-2020) 10.19.5 Sun Pharmaceutical Recent Development 13.20 Fosun Pharma 10.20.1 Fosun Pharma Company Details 10.20.2 Fosun Pharma Business Overview and Its Total Revenue 10.20.3 Fosun Pharma NSCLS Drugs Introduction 10.20.4 Fosun Pharma Revenue in NSCLS Drugs Business (2015-2020) 10.20.5 Fosun Pharma Recent Development 14Analyst's Viewpoints/Conclusions 15Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source 15.2 Disclaimer 15.3 Author Details

List of Tables Table 1. NSCLS Drugs Key Market Segments Table 2. Key Players Covered: Ranking by NSCLS Drugs Revenue Table 3. Ranking of Global Top NSCLS Drugs Manufacturers by Revenue (US$ Million) in 2019 Table 4. Global NSCLS Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026 Table 5. Key Players of EGFR Targeting Table 6. Key Players of ALK Targeting Table 7. Key Players of PD-1/PD-L1 Targeting Table 8. Key Players of Gemcitabine Table 9. Key Players of Cisplatin/Carboplatin Table 10. Key Players of Pemetrexed Table 11. Key Players of Paclitaxel Table 12. Key Players of Others Table 13. Global NSCLS Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026 Table 14. Global NSCLS Drugs Market Size by Regions (US$ Million): 2020 VS 2026 Table 15. Global NSCLS Drugs Market Size by Regions (2015-2020) (US$ Million) Table 16. Global NSCLS Drugs Market Share by Regions (2015-2020) Table 17. Global NSCLS Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million) Table 18. Global NSCLS Drugs Market Share by Regions (2021-2026) Table 19. Market Top Trends Table 20. Key Drivers: Impact Analysis Table 21. Key Challenges Table 22. NSCLS Drugs Market Growth Strategy Table 23. Main Points Interviewed from Key NSCLS Drugs Players Table 24. Global NSCLS Drugs Revenue by Players (2015-2020) (Million US$) Table 25. Global NSCLS Drugs Market Share by Players (2015-2020) Table 26. Global Top NSCLS Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in NSCLS Drugs as of 2019) Table 27. Global NSCLS Drugs by Players Market Concentration Ratio (CR5 and HHI) Table 28. Key Players Headquarters and Area Served Table 29. Key Players NSCLS Drugs Product Solution and Service Table 30. Date of Enter into NSCLS Drugs Market Table 31. Mergers & Acquisitions, Expansion Plans Table 32. Global NSCLS Drugs Market Size by Type (2015-2020) (Million US$) Table 33. Global NSCLS Drugs Market Size Share by Type (2015-2020) Table 34. Global NSCLS Drugs Revenue Market Share by Type (2021-2026) Table 35. Global NSCLS Drugs Market Size Share by Application (2015-2020) Table 36. Global NSCLS Drugs Market Size by Application (2015-2020) (Million US$) Table 37. Global NSCLS Drugs Market Size Share by Application (2021-2026) Table 38. North America Key Players NSCLS Drugs Revenue (2019-2020) (Million US$) Table 39. North America Key Players NSCLS Drugs Market Share (2019-2020) Table 40. North America NSCLS Drugs Market Size by Type (2015-2020) (Million US$) Table 41. North America NSCLS Drugs Market Share by Type (2015-2020) Table 42. North America NSCLS Drugs Market Size by Application (2015-2020) (Million US$) Table 43. North America NSCLS Drugs Market Share by Application (2015-2020) Table 44. Europe Key Players NSCLS Drugs Revenue (2019-2020) (Million US$) Table 45. Europe Key Players NSCLS Drugs Market Share (2019-2020) Table 46. Europe NSCLS Drugs Market Size by Type (2015-2020) (Million US$) Table 47. Europe NSCLS Drugs Market Share by Type (2015-2020) Table 48. Europe NSCLS Drugs Market Size by Application (2015-2020) (Million US$) Table 49. Europe NSCLS Drugs Market Share by Application (2015-2020) Table 50. China Key Players NSCLS Drugs Revenue (2019-2020) (Million US$) Table 51. China Key Players NSCLS Drugs Market Share (2019-2020) Table 52. China NSCLS Drugs Market Size by Type (2015-2020) (Million US$) Table 53. China NSCLS Drugs Market Share by Type (2015-2020) Table 54. China NSCLS Drugs Market Size by Application (2015-2020) (Million US$) Table 55. China NSCLS Drugs Market Share by Application (2015-2020) Table 56. Japan Key Players NSCLS Drugs Revenue (2019-2020) (Million US$) Table 57. Japan Key Players NSCLS Drugs Market Share (2019-2020) Table 58. Japan NSCLS Drugs Market Size by Type (2015-2020) (Million US$) Table 59. Japan NSCLS Drugs Market Share by Type (2015-2020) Table 60. Japan NSCLS Drugs Market Size by Application (2015-2020) (Million US$) Table 61. Japan NSCLS Drugs Market Share by Application (2015-2020) Table 62. Southeast Asia Key Players NSCLS Drugs Revenue (2019-2020) (Million US$) Table 63. Southeast Asia Key Players NSCLS Drugs Market Share (2019-2020) Table 64. Southeast Asia NSCLS Drugs Market Size by Type (2015-2020) (Million US$) Table 65. Southeast Asia NSCLS Drugs Market Share by Type (2015-2020) Table 66. Southeast Asia NSCLS Drugs Market Size by Application (2015-2020) (Million US$) Table 67. Southeast Asia NSCLS Drugs Market Share by Application (2015-2020) Table 68. India Key Players NSCLS Drugs Revenue (2019-2020) (Million US$) Table 69. India Key Players NSCLS Drugs Market Share (2019-2020) Table 70. India NSCLS Drugs Market Size by Type (2015-2020) (Million US$) Table 71. India NSCLS Drugs Market Share by Type (2015-2020) Table 72. India NSCLS Drugs Market Size by Application (2015-2020) (Million US$) Table 73. India NSCLS Drugs Market Share by Application (2015-2020) Table 74. Central & South America Key Players NSCLS Drugs Revenue (2019-2020) (Million US$) Table 75. Central & South America Key Players NSCLS Drugs Market Share (2019-2020) Table 76. Central & South America NSCLS Drugs Market Size by Type (2015-2020) (Million US$) Table 77. Central & South America NSCLS Drugs Market Share by Type (2015-2020) Table 78. Central & South America NSCLS Drugs Market Size by Application (2015-2020) (Million US$) Table 79. Central & South America NSCLS Drugs Market Share by Application (2015-2020) Table 80. Roche Company Details Table 81. Roche Business Overview Table 82. Roche Product Table 83. Roche Revenue in NSCLS Drugs Business (2015-2020) (Million US$) Table 84. Roche Recent Development Table 85. Novartis Company Details Table 86. Novartis Business Overview Table 87. Novartis Product Table 88. Novartis Revenue in NSCLS Drugs Business (2015-2020) (Million US$) Table 89. Novartis Recent Development Table 90. Pfizer Company Details Table 91. Pfizer Business Overview Table 92. Pfizer Product Table 93. Pfizer Revenue in NSCLS Drugs Business (2015-2020) (Million US$) Table 94. Pfizer Recent Development Table 95. Merck Company Details Table 96. Merck Business Overview Table 97. Merck Product Table 98. Merck Revenue in NSCLS Drugs Business (2015-2020) (Million US$) Table 99. Merck Recent Development Table 100. Bristol-Myers Squibb Company Details Table 101. Bristol-Myers Squibb Business Overview Table 102. Bristol-Myers Squibb Product Table 103. Bristol-Myers Squibb Revenue in NSCLS Drugs Business (2015-2020) (Million US$) Table 104. Bristol-Myers Squibb Recent Development Table 105. Eli Lilly and Company Company Details Table 106. Eli Lilly and Company Business Overview Table 107. Eli Lilly and Company Product Table 108. Eli Lilly and Company Revenue in NSCLS Drugs Business (2015-2020) (Million US$) Table 109. Eli Lilly and Company Recent Development Table 110. Takeda Pharmaceutical Company Details Table 111. Takeda Pharmaceutical Business Overview Table 112. Takeda Pharmaceutical Product Table 113. Takeda Pharmaceutical Revenue in NSCLS Drugs Business (2015-2020) (Million US$) Table 114. Takeda Pharmaceutical Recent Development Table 115. Boehringer-Ingelheim Business Overview Table 116. Boehringer-Ingelheim Product Table 117. Boehringer-Ingelheim Company Details Table 118. Boehringer-Ingelheim Revenue in NSCLS Drugs Business (2015-2020) (Million US$) Table 119. Boehringer-Ingelheim Recent Development Table 120. AstraZeneca Company Details Table 121. AstraZeneca Business Overview Table 122. AstraZeneca Product Table 123. AstraZeneca Revenue in NSCLS Drugs Business (2015-2020) (Million US$) Table 124. AstraZeneca Recent Development Table 125. Betta Pharmaceuticals Company Details Table 126. Betta Pharmaceuticals Business Overview Table 127. Betta Pharmaceuticals Product Table 128. Betta Pharmaceuticals Revenue in NSCLS Drugs Business (2015-2020) (Million US$) Table 129. Betta Pharmaceuticals Recent Development Table 130. Qilu Oharmaceutical Company Details Table 131. Qilu Oharmaceutical Business Overview Table 132. Qilu Oharmaceutical Product Table 133. Qilu Oharmaceutical Revenue in NSCLS Drugs Business (2015-2020) (Million US$) Table 134. Qilu Oharmaceutical Recent Development Table 135. Pierre Fabre Medicament Company Details Table 136. Pierre Fabre Medicament Business Overview Table 137. Pierre Fabre Medicament Product Table 138. Pierre Fabre Medicament Revenue in NSCLS Drugs Business (2015-2020) (Million US$) Table 139. Pierre Fabre Medicament Recent Development Table 140. Chemo Wanbang Biopharma Company Details Table 141. Chemo Wanbang Biopharma Business Overview Table 142. Chemo Wanbang Biopharma Product Table 143. Chemo Wanbang Biopharma Revenue in NSCLS Drugs Business (2015-2020) (Million US$) Table 144. Chemo Wanbang Biopharma Recent Development Table 145. Hetero Drugs Company Details Table 146. Hetero Drugs Business Overview Table 147. Hetero Drugs Product Table 148. Hetero Drugs Revenue in NSCLS Drugs Business (2015-2020) (Million US$) Table 149. Hetero Drugs Recent Development Table 150. Harbin Gloria Pharmaceuticals Company Details Table 151. Harbin Gloria Pharmaceuticals Business Overview Table 152. Harbin Gloria Pharmaceuticals Product Table 153. Harbin Gloria Pharmaceuticals Revenue in NSCLS Drugs Business (2015-2020) (Million US$) Table 154. Harbin Gloria Pharmaceuticals Recent Development Table 155. Luoxin Pharmaceutical Company Details Table 156. Luoxin Pharmaceutical Business Overview Table 157. Luoxin Pharmaceutical Product Table 158. Luoxin Pharmaceutical Revenue in NSCLS Drugs Business (2015-2020) (Million US$) Table 159. Luoxin Pharmaceutical Recent Development Table 160. Teva Pharmaceutical Company Details Table 161. Teva Pharmaceutical Business Overview Table 162. Teva Pharmaceutical Product Table 163. Teva Pharmaceutical Revenue in NSCLS Drugs Business (2015-2020) (Million US$) Table 164. Teva Pharmaceutical Recent Development Table 165. Mylan Company Details Table 166. Mylan Business Overview Table 167. Mylan Product Table 168. Mylan Revenue in NSCLS Drugs Business (2015-2020) (Million US$) Table 169. Mylan Recent Development Table 170. Sun Pharmaceutical Company Details Table 171. Sun Pharmaceutical Business Overview Table 172. Sun Pharmaceutical Product Table 173. Sun Pharmaceutical Revenue in NSCLS Drugs Business (2015-2020) (Million US$) Table 174. Sun Pharmaceutical Recent Development Table 175. Fosun Pharma Company Details Table 176. Fosun Pharma Business Overview Table 177. Fosun Pharma Product Table 178. Fosun Pharma Revenue in NSCLS Drugs Business (2015-2020) (Million US$) Table 179. Fosun Pharma Recent Development Table 180. Research Programs/Design for This Report Table 181. Key Data Information from Secondary Sources Table 182. Key Data Information from Primary Sources List of Figures Figure 1. Global NSCLS Drugs Market Share by Type: 2020 VS 2026 Figure 2. EGFR Targeting Features Figure 3. ALK Targeting Features Figure 4. PD-1/PD-L1 Targeting Features Figure 5. Gemcitabine Features Figure 6. Cisplatin/Carboplatin Features Figure 7. Pemetrexed Features Figure 8. Paclitaxel Features Figure 9. Others Features Figure 10. Global NSCLS Drugs Market Share by Application: 2020 VS 2026 Figure 11. ≤ 30 Years Old Case Studies Figure 12. 31 - 45 Years Old Case Studies Figure 13. 46 - 60 Years Old Case Studies Figure 14. ＞ 60 Years Old Case Studies Figure 15. NSCLS Drugs Report Years Considered Figure 16. Global NSCLS Drugs Market Size YoY Growth 2015-2026 (US$ Million) Figure 17. Global NSCLS Drugs Market Share by Regions: 2020 VS 2026 Figure 18. Global NSCLS Drugs Market Share by Regions (2021-2026) Figure 19. Porter's Five Forces Analysis Figure 20. Global NSCLS Drugs Market Share by Players in 2019 Figure 21. Global Top NSCLS Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in NSCLS Drugs as of 2019 Figure 22. The Top 10 and 5 Players Market Share by NSCLS Drugs Revenue in 2019 Figure 23. North America NSCLS Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 24. Europe NSCLS Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 25. China NSCLS Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 26. Japan NSCLS Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 27. Southeast Asia NSCLS Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 28. India NSCLS Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 29. Central & South America NSCLS Drugs Market Size YoY Growth (2015-2020) (Million US$) Figure 30. Roche Total Revenue (US$ Million): 2019 Compared with 2018 Figure 31. Roche Revenue Growth Rate in NSCLS Drugs Business (2015-2020) Figure 32. Novartis Total Revenue (US$ Million): 2019 Compared with 2018 Figure 33. Novartis Revenue Growth Rate in NSCLS Drugs Business (2015-2020) Figure 34. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018 Figure 35. Pfizer Revenue Growth Rate in NSCLS Drugs Business (2015-2020) Figure 36. Merck Total Revenue (US$ Million): 2019 Compared with 2018 Figure 37. Merck Revenue Growth Rate in NSCLS Drugs Business (2015-2020) Figure 38. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018 Figure 39. Bristol-Myers Squibb Revenue Growth Rate in NSCLS Drugs Business (2015-2020) Figure 40. Eli Lilly and Company Total Revenue (US$ Million): 2019 Compared with 2018 Figure 41. Eli Lilly and Company Revenue Growth Rate in NSCLS Drugs Business (2015-2020) Figure 42. Takeda Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018 Figure 43. Takeda Pharmaceutical Revenue Growth Rate in NSCLS Drugs Business (2015-2020) Figure 44. Boehringer-Ingelheim Total Revenue (US$ Million): 2019 Compared with 2018 Figure 45. Boehringer-Ingelheim Revenue Growth Rate in NSCLS Drugs Business (2015-2020) Figure 46. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018 Figure 47. AstraZeneca Revenue Growth Rate in NSCLS Drugs Business (2015-2020) Figure 48. Betta Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018 Figure 49. Betta Pharmaceuticals Revenue Growth Rate in NSCLS Drugs Business (2015-2020) Figure 50. Qilu Oharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018 Figure 51. Qilu Oharmaceutical Revenue Growth Rate in NSCLS Drugs Business (2015-2020) Figure 52. Pierre Fabre Medicament Total Revenue (US$ Million): 2019 Compared with 2018 Figure 53. Pierre Fabre Medicament Revenue Growth Rate in NSCLS Drugs Business (2015-2020) Figure 54. Chemo Wanbang Biopharma Total Revenue (US$ Million): 2019 Compared with 2018 Figure 55. Chemo Wanbang Biopharma Revenue Growth Rate in NSCLS Drugs Business (2015-2020) Figure 56. Hetero Drugs Total Revenue (US$ Million): 2019 Compared with 2018 Figure 57. Hetero Drugs Revenue Growth Rate in NSCLS Drugs Business (2015-2020) Figure 58. Harbin Gloria Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018 Figure 59. Harbin Gloria Pharmaceuticals Revenue Growth Rate in NSCLS Drugs Business (2015-2020) Figure 60. Luoxin Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018 Figure 61. Luoxin Pharmaceutical Revenue Growth Rate in NSCLS Drugs Business (2015-2020) Figure 62. Teva Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018 Figure 63. Teva Pharmaceutical Revenue Growth Rate in NSCLS Drugs Business (2015-2020) Figure 64. Mylan Total Revenue (US$ Million): 2019 Compared with 2018 Figure 65. Mylan Revenue Growth Rate in NSCLS Drugs Business (2015-2020) Figure 66. Sun Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018 Figure 67. Sun Pharmaceutical Revenue Growth Rate in NSCLS Drugs Business (2015-2020) Figure 68. Fosun Pharma Total Revenue (US$ Million): 2019 Compared with 2018 Figure 69. Fosun Pharma Revenue Growth Rate in NSCLS Drugs Business (2015-2020) Figure 70. Bottom-up and Top-down Approaches for This Report Figure 71. Data Triangulation Figure 72. Key Executives Interviewed

Roche Novartis Pfizer Merck Bristol-Myers Squibb Eli Lilly and Company Takeda Pharmaceutical Boehringer-Ingelheim AstraZeneca Betta Pharmaceuticals Qilu Oharmaceutical Pierre Fabre Medicament Chemo Wanbang Biopharma Hetero Drugs Harbin Gloria Pharmaceuticals Luoxin Pharmaceutical Teva Pharmaceutical Mylan Sun Pharmaceutical Fosun Pharma